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The metastasis is the spread of cancer from one part of the body to another. Two-thirds of patients with cancer will develop bone
metastasis. Breast, prostate and lung cancer are responsible for more than 80% of cases of metastatic bone disease. The spine is
the most common site of bone metastasis. A spinal metastasis may cause pain, instability and neurological injuries. The diﬀusion
through Batson venous system is the principal process of spinal metastasis, but the dissemination is possible also through arterial
and lymphatic system or by contiguity. Once cancer cells have invaded the bone, they produce growth factors that stimulate
osteoblastic or osteolytic activity resulting in bone remodeling with release of other growth factors that lead to a vicious cycle of
bone destruction and growth of local tumour.
1.Introduction
The metastasis is the spread of cancer from one part, where
it started (called its primary site) of the body to another.
A tumour formed by cells that have spread is called a
“metastatic tumour” or a “metastasis.” The metastatic tum-
our contains cells that are like those in the original (primary)
tumour[1].Whencellsbreakawayfromacanceroustumour,
they can travel to other areas of the body through the
bloodstream or lymph system. From there, they can end up
in any organ or tissue. Many of the cancer cells that break oﬀ
from the original tumour die without causing any problems.
Some, however, settle in a new area. There, they begin to
growandformnewtumours.Sometimesmetastatictumours
are found by tests that are done when the primary cancer is
ﬁrst diagnosed. In other cases, the metastasis is found ﬁrst,
causingthedoctortolookfortheplacethatthecancerstarted
[2, 3].
2. Epidemiology
Approximately two-thirds of patients with cancer will
developbonemetastasis[4].Oftheestimated569,490people
who will die of cancer in 2010, almost all will have metastasis
to some part of the body. It is estimated that about 350,000
peoplediewithbonemetastasiseachyearintheUnitedStates
[5]. Sometimes bone metastasis is not clinically visible and
their demonstration occurs during autopsy; therefore, the
real incidence of bone metastasis is not possible to report
[6]. Bone metastasis is actually much more common than
primary bone cancers [2, 7] because the incidence is 25/1
and they are the neoplastic lesions more seen by orthopedist
[8, 9]. Bones are the most common place for metastasis
after lung and liver [2, 3, 10]. Primary tumors that most
often leads to bone metastasis are in the order of incidence:
prostate, breast, kidney, lung, and thyroid cancer [6]. The
incidence of skeletal metastasis from autopsy studies is of
73% (range of 47–85%) in the breast cancer, 68% (range
of 33–85%) in the prostate cancer, 42% (range of 28–60%)
in the thyroid cancer, 36% (range of 30–55%) in the lung
cancer, 35% (range of 33–40%) in the kidney cancer, 6%
(range of of 5–7%) in the esophageal cancer, 5% (range of
3–11%) in the gastrointestinal tract cancers, 11% (range of
8–13%) in the rectal cancer [11]. Given the high prevalence
of breast, prostate, and lung cancer, they are responsible for
more than 80% of cases of metastatic bone disease [12].2 International Journal of Surgical Oncology
According to Roodman GD, up to 70% of patients with
breast cancer or prostate cancer, and 15 to 30% of patients
with lung, colon, bladder, or kidney cancer develop bone
metastasis[13].Breastcanceristhemostcommonmalignant
tumour and the main cause of bone metastasis in women
[14]. About 70% of people who die from breast cancer will
have radiological evidence of skeletal metastasis before their
death and in 40% of cases the bone is the ﬁrst metastatic
site [11]; the estrogen receptors [11], the sialoprotein [15],
the parathyroid-related peptide (PTHrP) [16], and 69 gene
signature correlated with ﬁbroblasts growth factors [17]a r e
predictive markers of bone recurrence [12]. While prostate
and lung metastasis are those that occur more in men [14].
The primary tumor cannot be determined in 9% of cases of
spinal metastases [18].
3.Locationsof SpineMetastasis
Metastasis can occur in any bone in the body but is most
often found in bones near the center of the body. The spine
is the most common site of bone metastasis [2, 12]. It is esti-
mated that over the 10% of patients with cancer will develop
a symptomatic spinal metastasis [19, 20]. Algra et al. suggest
that the initial anatomic location of metastases within
vertebrae is in the posterior portion of the body. Analysis of
CT scans shows that the body is involved before the pedicles,
although destruction of the pedicles is the most common
ﬁnding on plain ﬁlms. Destruction of the pedicles occurs
only in combination with the involvement of the vertebral
body [21]. Other common sites are the hip bone (pelvis),
upper leg bone (femur), upper arm bone (humerus), ribs,
and the skull [2, 14]. Studies showed that the thoracic spine
istheregionmoreinvolvedwithmetastasis[22],whileothers
studies highlighted how the lumbar spine is more involved
[23, 24]. The cervical spine is the least involved (10%)
[14]. More than 50% of patients with spinal metastasis have
multiple levels involved, and 10 to 38% of patients have
multiple, noncontiguous segments involved [14]. The lung
and breast cancers metastasize preferably in the thoracic
region because the venous drainage of the breast through
the azygos communicates with the plexus of Batson in the
thoracicregion[21,23,25],whilelungcancerdrainsthrough
the pulmonary veins in the left heart and from there is
distributedinthegeneralizedmannerintheskeletal;prostate
cancer metastasizes usually to the lumbar-sacral spine and
pelvis,becauseitdrainsthroughthepelvicplexusinthelum-
bar region [25]. Colon and rectal tumors usually metastasize
through the portal system in the liver and lung, and only late
in skeletal [14].
4. Symptoms of Bones andSpineMetastasis
Bone metastasis is one of the most frequent causes of pain in
peoplewithcancer.Whenacancerspreadstothebone,itcan
makethebonesweakerandevencausethemtobreakwithout
an injury [2, 7]. As the cancer cells damage the bones,
calcium is released into the blood. This can lead to problems
from high blood calcium levels. Bone metastasis can also
cause other problems that can limit your ability to keep up
your usual activities and lifestyle [2]. A spinal metastasis may
cause pain, instability, neurological injuries with loss of con-
trol urinary and rectal sphincter up to paraplegia. However,
60% of all bone metastasis [26] and 36% of vertebral lesions
[27] are asymptomatic and discovered occasionally. Symp-
tomaticspinalcordinvolvementoccursin18000patientsper
year [18]. Brihaye et al. analyzed 1477 cases concluded that
16.5% of spinal metastases with epidural involvement came
from the breast cancer, 15.6% from the lung cancer, 9.2%
fromprostatecancer,and6.5%fromkidneycancer;theyalso
analyzed 1585 cases of symptomatic epidural metastases and
reported that 70.3% had involvement of thoracic and thora-
columbar region, 21.6% of the lumbar and sacral region, and
8.1% of the cervical and cervical-thoraco region, concluding
that although the lumbar region is more involved, the ma-
jorityofpatientswithneurologicaldysfunctionhavethoracic
lesions [28].
5.Prognosis
Once cancer has spread to the bones or to other sites in
the body, it is rarely able to be cured, but often it can still
be treated to shrink, stop, or slow its growth. Even if cure
is no longer possible, treating the cancer may be able to
help you live longer and feel better [2]. The diagnosis of
metastasis changes the patients’ prognosis; according to data
from the ACS, the survival rate at ﬁve years in nonmetastatic
carcinomas treated from 1996 to 2002 was of 100% in
prostate cancer, 97% in the thyroid cancer, 89% in the breast
cancer,66%inthekidneycancer,and16%inthelungcancer;
in the same period, in the metastatic tumors at presentation,
the ﬁve-year survival rate was of 56% in thyroid cancer, 33%
in prostate cancer, 26% in breast cancer, 10% in renal cancer,
and 2% in lung cancer [29].
6. Method of Dissemination
The cancer can metastasize in the bone through diﬀerent
ways of propagation: the most frequent is the hematogenous
way, the intravenous one for lesions of the spinal column,
andthearterialoneforlesionsthatatthebeginningareprox-
imal (shoulder and pelvis) and then distal (elbow and knee).
Less frequent lesions are those ones by contiguity and even
less frequent are those ones for lymphatic spread (whose role
is not well deﬁned) [6, 14]. The diﬀusion through the venous
system is the principal process of spinal metastasis. In 1940,
Batson (Figure 1) demonstrated by injecting contrast into
the vein of the penis in males and into the veins of the breast
in women that the contrast and so the tumor cells spread in
thebloodintothespinalveinsasaresultofvenousreﬂuxthat
occurred after an increase of intrathoracic pressure and/or
intra-abdominal as for a Valsalva maneuver [30]. It was an
explanationofthepossibility ofthediﬀusionofbreastcancer
in the column that is drained mainly by the azygos vein
which communicates with the paravertebral venous plexus
of Batson in the thoracic region and prostate cancer that is
drained from the venous plexus which communicates with
the pelvic plexus of Batson at the lumbar [31]. This hypoth-
esis was conﬁrmed by the study of Coman and DeLong, whoInternational Journal of Surgical Oncology 3
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Figure 1: Batson venous plexus, from Batson O.V., “The function of the vertebral veins and their role in the spread of metastases,” Ann Surg.
1940 July; 112 (1): 138–149.
noted that lumbar spinal tumor metastasis appeared in 70%
of the animals, injecting cancer cells into the femoral vein
of rats, when an external abdominal pressure was carried
out [23, 32]. The venous plexus of Batson is a system of
veinslocatedintheepiduralspacebetweenthespinalcolumn
bone and the dura mater, with no valves that control the
ﬂow of blood, so that each increase of pressure in the system
of the vena cava results in an increased ﬂow level of the
plexus. It is connected to the portal and caval system that in
normal conditions deviate 5–10% of blood in the vertebral
venous system and with the latter [14, 23, 30, 33, 34]. Cancer
cells may metastasize through the blood system and into the
vertebral body directly through the nutrient arteries as in the
case of lung cancer [14, 35]. Arguello et al. showed that the
injection of a variety of tumor cells into the systems arterial
circulationofmiceresultedinasyndromeoftumorcoloniza-
tion of the vertebra followed by a spinal cord compression
[36]. The direct diﬀusion of prostate cancer at the lumbar4 International Journal of Surgical Oncology
spine and the direct diﬀusion of the breast and lung ones at
the thoracic spine are other methods of spreading [14].
7.Mechanismof Localizationof
MetastasesinBone
The development of a bone metastasis is not a simple process
of transport, arrest, and growth of cancer cells in these
spaces. Before moving to the bone marrow and taking root
and growing in its spaces, neoplastic cells have to follow a
long route [37]. They must ﬁrst spread through the primary
site at the expense of the preexisting cells and stroma then
detach from it by the reduction of adhesion molecules and
the opening of the epithelial basal lamina, afterwards reach
the blood vessels and penetrate into them by degradation
of their basal lamina and endothelium, then migrate with
the bloodstream and escape the surveillance of the immune
cells, reach the bone marrow sinusoids, stop and grow there
[38, 39]. These processes mainly occur through the activity
of proteinases, such as the metalloproteinases, the serine,
cysteine, and aspartic proteinases [40–53], stromelysin [54],
uPA [55, 56]. These proteinases destroy the epithelial basal
lamina and the surrounding tissue by degradation of type
IV collagen, laminin, proteoglycans, and other proteins but
alsouncoverhiddenbiologicactivitiesandreducecell-to-cell
adhesion by interfering with adhesion receptors in the cell
membrane [47, 57]. Tumour-host interactions are mediated
by a number of cell surface adhesion molecules which
belong to the four superfamilies of integrins, cadherins,
immunoglobulins, and selectins. The acquisition of invasive
and diﬀusive properties by cancer cells are clearly connected
with changes in these molecules, especially a fall in the
expression of E-cadherin and a rise in that of CD44 [58].
The expression of adhesion molecules such as integrins
αIIbβ3a n dαLβ2, or PECAM-1, ICAM-1 and N-CAM, plays
a relevant role in the interaction of cancer cells with the
endothelium and matrix [59–61]. Preferential localization in
skeletal segments which contain red bone marrow (vertebral
bodies, ribs, iliac bones, the sternum, the femoral head, the
epiphysis of long bones) can be explained by the fact that
the rich vascularity allows cancer cells to be transported to
this level and reduced blood ﬂow velocity [62], together with
the formation of vortices and/or microthrombi, promotes
the adhesion and immobilization of the tumour cells on
the endothelial ones. Another theory suggests that neoplastic
cells migrate to and localize in a preferential target tissue
becausethatiswheretheyﬁndthemostfertile“soil”inwhich
to grow, because the bone and bone marrow cells contain
and express a variety of growth factors, cytokines, enzymes,
and hormone-like substances which, together with similar
factorsproducedbycancercells,canmakethebonemicroen-
vironment (the “soil”) suitable for cellular implantation (the
“seeding”) and development [39, 63–66]. MMPs, BSP, and
OPN play a key role in the implantation of neoplastic cells in
bone marrow by degrading the extracellular matrix modify-
ing cell-cell and cell-matrix contacts and interactions regula-
tion of attachment and chemotactic migration of endothelial
cells, and the promotion of angiogenesis [40, 49, 57, 67, 68].
After their localization in bone marrow spaces, their growth
to clinically manifest metastases depends on a number of
promoting or inhibiting conditions, primarily on interaction
with surrounding bone and bone marrow cells, through the
increased expression of adhesion molecules, the availability
of space, degree of vascularity, and type of bone remodelling.
The development of a metastasis obviously depends on
the proliferation of neoplastic cells, but other processes are
critical in this connection, primarily neo-angiogenesis [69].
8. Pathogenesis
The bone tissue undergoes a continuous process of resorp-
tion by the action of osteoclasts, and remodelling, through
the action of osteoblasts. In normal individuals, this process
isbalanced.Incancercells,thisbalanceislostandlytic,thick-
ener, or mixed lesions are created [12, 13]. The osteolytic
lesions are caused by stimulation of osteoclastic activity
accompanied by reduced osteoblastic activity not by direct
eﬀects of tumour cells on the bone [70, 71]. The osteoblastic
lesionsareexpressionofanincreasedboneformationaround
the tumour cells associated with a disequilibrium of the
osteolytic activity and with an altered turnover of the bone
[71]. Once cancer cells have invaded the bone, they produce
growth factors that directly stimulate osteoclastic activity
and/or osteoblastic activity resulting in bone remodelling
and further release of growth factors that lead to a vicious
cycle of bone destruction and growth of local tumour [13,
71, 72].
9. Osteolytic MetastasisPathogenesis
Tumour cells produce IL-1-6-8-11, PgE2, TGFα,T G F β,
EGF, VEGF, TNF, CSF-1, GM-CSF, and M-CSF, which can
directly or indirectly stimulate osteoclastic activity and then
bone resorption [5, 12, 13, 72, 73]. Proteolytic enzymes,
as acid phosphatase, acid hydrolase, alkaline phosphatise
[74], metalloproteinase MMP-2, MMP-9, and K cathepsin
seemed to be involved in the early phase of bone metastasis
formation degrading bone basal membrane, facilitating
tumoral diﬀusion and bone matrix cytokine release and
stimulating tumour cell proliferation [75]. Tumour cells may
increase bone resorption also stimulating the tumour-linked
immune response with release of osteoclastic activating
factors [76]. PTHrP produced by breast cancer cells plays a
key role in bone resorption stimulating osteoclastic activity
[77, 78]; it is more present in metastatic breast cancer
(92%) than in not metastatic ones (50% ) [79]. PTHrP and
IL 1-6-11 induce osteoclastic bone resorption stimulating
osteoblasts and stromal cells to produce the receptor acti-
vator of nuclear factor-kB (RANK) ligand; this factor links
to its receptor on the osteoclastic precursors inducing their
proliferation and diﬀerentiation (Figure 2)[ 76]. The bone
damage consequently obtained facilitates the growth factors
release causing tumour cells proliferation, as TGFβ, IGFs,
FGFs, PDGF, BMPs, which stimulates PTHrP production
and then osteolysis [12, 80]. So a vicious circle is present
(Figure 3): osteolysis and growth factors release stimulate
tumour cells proliferation and then metastatic cells growth
[72, 80]. Usually OPG production by osteoblasts neutralizesInternational Journal of Surgical Oncology 5
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Figure 2: Receptor Activator of Nuclear Factor k B Ligand (RANK)
and Osteoclast Formation, from Roodman G. D., “Mechanisms of
bone metastasis,” NE n g lJM e d . , 15; 350 (16): 1655–64, Apr 2004.
RANK ligand locking osteclastic stimulation, but it has
been demonstrated that OPG release is reduced in MCF-7
estrogen-dependent breast cancer cell line stimulating also
osteoclastic activity [81]. Also IL-6 expressed in prostate and
breast cancer cells stimulates osteoclasts cells strengthening
the eﬀects of PTHrP onto osteoclasts [82, 83].
10. Osteoblastic MetastasisPathogenesis
Bone blastic metastasis is usually present in prostate cancer.
Growth factors as TFGβ, PDGF, BMPs, IGFs, FGFs, and l’u-
PA (which stimulates TGFβ release) have been isolated in
prostate cancer cells and stimulate osteoblastic diﬀerentia-
tion and they have a role in growing and survival tumour
cells itself [70, 74, 84, 85]. It has been demonstrated that
endothelin 1 level is elevated in bone metastatic prostate
tumours than in nonmetastatic ones [86]. It stimulates os-
teoblastic activity and inhibits the osteoclastic one [87],
increases cancer cells proliferation, and stimulates the other
growthfactorsmitogeneﬀects[88];itsproductionisreduced
by androgens and is increased in the androgen-resistant
diseases [89]; it is important because usually prostate cancer
develops androgene resistance. ET-1 antagonists reduce
eitherosteoblasticbonemetastaticgrowthortumourgrowth
[90]. Also PTHrP and its receptor have been found in bone
metastases and in primary prostate cancer, and it has been
demonstrated that prostate tumour cells are able to directly
express a form of RANK ligand, which directly induces bone
resorption [91], revealing that osteolytic activity is present in
prostate cancer [92]. Bone degradation products have been
found in urine leading to the hypothesis that in prostate
cancerthereisatthebeginninganosteolyticactivityfollowed
by high osteoblastic one [93]. Another study demonstrated
that the insertion of PC-3 tumour cells in SCID mice tibia
caused osteolytic lesions due to RANK ligand, while other
cell lines caused osteoblastic ones, so authors reported that
osteoclastic activity is not a prerequisite for osteoblastic
lesions [94]. Further study is necessary for this [13]. More-
over, in prostate cancer Wnt induces osteoblastic activity,
thatintheearlyphasemaybebalancedbyDKK1Wntagonist
(an osteoblastic diﬀerentiate inhibitor), leading to lythic
Cancer cells
Osteoclast
Bone
Interleukin-6, PGE2,
tumor necrosis
factor, M-CSF
Parathyroid
hormone-related
peptide
TGF-β, IGFs, FGFs, PDGF, BMPs
Figure 3: The Vicious Circle of Osteolytic Metastasis, from Rood-
manG.D.,“Mechanismsofbonemetastasis,”NE nglJM ed.,15;350
(16): 1655–64, Apr 2004.
lesions. After the tumour progression, the balance between
Wnt and its inhibitors is shifted towards the ﬁrst, promoting
osteoblastic lesions [95, 96]. Nevertheless, PSA tumour-
induced can block PTHrP [97] and then bone resorption
and activating osteoblastic growth factors as TGFβ,l ’ I G F - 1
released by bone during metastastic development, leading to
a vicious circle also for osteoblastic lesions [13].
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